Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:dateCreated |
1992-7-8
|
pubmed:abstractText |
Cefpodoxime proxetil is the orally absorbed ester of cefpodoxime, a new third generation cephalosporin. In the gastrointestinal tract, cefpodoxime proxetil is hydrolysed to cefpodoxime, which has potent antibacterial activity against the major bacterial pathogens involved in lower respiratory tract infections: Haemophilus influenzae, Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains), and Streptococcus pneumoniae (including amoxicillin-resistant strains). Six randomised comparative studies in patients with lower respiratory tract infections, 5 of which were large (enrollment of more than 200 patients) and double-blind, examined the efficacy and safety of cefpodoxime proxetil. Cefpodoxime proxetil (at a dosage equivalent to 200mg of cefpodoxime) administered twice daily for 5 to 10 days was similar in clinical and bacteriological efficacy to the following: amoxicillin 500mg 3 times daily in the treatment of community-acquired pneumonia; intramuscular ceftriaxone Ig once daily in the treatment of pulmonary infections in hospitalised patients; and to amoxicillin/clavulanic acid 500/125mg 3 times daily in the treatment of acute exacerbations of chronic bronchitis (AECB). Additionally, a dosage equivalent to 100mg or 200mg of cefpodoxime twice daily was similar in clinical and bacteriological efficacy to amoxicillin 250mg 3 times daily in the treatment of bronchitis (acute or AECB). The adverse events noted with cefpodoxime proxetil administration were similar to those associated with other beta-lactam antibacterials and most commonly involved the gastrointestinal tract and skin or mucous membranes. Thus, cefpodoxime proxetil is a useful addition to the antibacterials available for the treatment of infections of the lower respiratory tract.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0012-6667
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
42 Suppl 3
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
34-40
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:1726206-Aged,
pubmed-meshheading:1726206-Bronchitis,
pubmed-meshheading:1726206-Ceftizoxime,
pubmed-meshheading:1726206-Haemophilus Infections,
pubmed-meshheading:1726206-Haemophilus influenzae,
pubmed-meshheading:1726206-Humans,
pubmed-meshheading:1726206-Moraxella (Branhamella) catarrhalis,
pubmed-meshheading:1726206-Neisseriaceae Infections,
pubmed-meshheading:1726206-Pneumococcal Infections,
pubmed-meshheading:1726206-Prodrugs,
pubmed-meshheading:1726206-Randomized Controlled Trials as Topic,
pubmed-meshheading:1726206-Respiratory Tract Infections,
pubmed-meshheading:1726206-Streptococcus pneumoniae
|
pubmed:year |
1991
|
pubmed:articleTitle |
Cefpodoxime proxetil in the treatment of lower respiratory tract infections.
|
pubmed:affiliation |
Department of Communicable and Tropical Diseases, East Birmingham Hospital, England.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Review
|